Key facts
- This page summarizes Donald A. Bergstrom's Form 4 filing for Relay Therapeutics, Inc. (RLAY).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Jun 2026, 16:09.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
Footnote F2
Includes 15,037 shares underlying restricted stock units.
Footnote F3
This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F4
Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder vested in equal quarterly installments over the remaining thirty-six (36) months.